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ABSTRACT 
     Intracellular protein translocation plays a pivotal role in regulating complex 
biological processes, including cell death. The tumor suppressor p53 is a transcription 
factor activated by DNA damage and oxidative stress that also translocates from the 
cytosol into the mitochondrial matrix to facilitate necrotic cell death. However, specific 
inhibitors of p53 mitochondrial translocation are largely unknown. To explore the 
inhibitors of p53, we developed a bioluminescent probe to monitor p53 translocation 
from cytosol to mitochondria using luciferase fragment complementation assays. The 
probe is composed of a novel pair of luciferase fragments, the N-terminus of green click 
beetle luciferase CBG68 (CBGN) and multiple-complement luciferase fragment 
(McLuc1). The combination of luciferase fragments showed significant luminescence 
intensity and high signal-to-background ratio. When the p53 connected with McLuc1 
translocates from cytosol into mitochondrial matrix, CBGN in mitochondrial matrix 
enables to complement with McLuc1, resulting in the restoration of the luminescence. 
The luminescence intensity was significantly increased under hydrogen 
peroxide-induced oxidative stress following the complementation of CBGN and 
McLuc1. Pifithrin-µ, a selective inhibitor of p53 mitochondrial translocation, prevented 
the mitochondrial translocation of the p53 probe in a concentration-dependent manner. 
Furthermore, the high luminescence intensity made it easier to visualize the p53 
translocation at a single cell level under a bioluminescence microscope. This p53 
mitochondrial translocation assay is a new tool for high-throughput screening to identify 
novel p53 inhibitors, which could be developed as drugs to treat diseases in which 
necrotic cell death is a major contributor. This article is protected by copyright. All rights 
reserved 
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INTRODUCTION 
 P53 is the guardian of the genome and regulates cellular responses to numerous 
stresses. It is well characterized and recognized as tumor suppressor, most notably by 
acting as a transcription factor (Bieging and Attardi 2012; Bieging et al. 2014). 
Following DNA damage or potent cellular stress, p53 inhibits cellular proliferation 
and/or induces apoptotic cell death by transactivation of variety of genes, among which 
are cyclin dependent kinase inhibitor p21 and pro-apoptotic BAX (Bcl-2-associated X 
protein) or PUMA (p53 upregulated modulator of apoptosis) (Bieging and Attardi 2012; 
Reinhardt and Schumacher 2012; Vogelstein et al. 2000). In the presence of a low level 
of stress, p53 elicits DNA repair and antioxidant protein production to restore normal 
cellular function (Bieging et al. 2014; Levine and Oren 2009; Sablina et al. 2005). In 
addition to apoptotic and senescence regulation, p53 also controls genes for cellular 
metabolism (Maddocks and Vousden 2011), immune responses (Menendez et al. 2013), 
angiogenesis (Teodoro et al. 2006; Zhang et al. 2000), cell differentiation (Tedeschi and 
Di Giovanni 2009), motility, migration (Roger et al. 2006) and reproduction (Hu et al. 
2007). One of the most prominent activities of p53 independent of transcription is to 
induce cell death by acting on mitochondria in response to stress. There, p53 interacts 
with the apoptosis regulators of the BCL-2 family and promotes mitochondrial outer 
membrane (MOM) permeabilization, which triggers apoptosis (Chipuk et al. 2004; Leu 
et al. 2004; Marchenko and Moll 2014). 
Translocation of p53 to the mitochondria is not restricted to the MOM. In 
response to an oxidative insult p53 penetrates into the mitochondrial matrix and 
facilitates in opening of the mitochondrial permeability transition pore (MPTP) in the 
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inner mitochondrial membrane (Dashzeveg and Yoshida 2015; Marchenko and Moll 
2014; Vaseva et al. 2012). Persistent opening of the MPTP in response to sustained 
cytosolic calcium and/or reactive oxygen species elevations initiates necrotic cell death 
in a broad range of life threatening diseases including ischemia-reperfusion injury of the 
heart, brain and kidney, acute pancreatitis, muscular dystrophies and neuro-degeneration  
(Bernardi and Di Lisa 2015; Kwong and Molkentin 2015; Millay et al. 2008; Mukherjee 
et al. 2016; Vaseva et al. 2012). To avoid necrotic cell death caused by these diseases, 
inhibitors of p53 mitochondrial translocation are strong candidates for the therapeutic 
agents.   
To explore the inhibitors of p53 mitochondrial translocation using living cells, a 
method for high-throughput drug screening system is needed. To visualize translocation 
of a protein into a specific organelle, fluorescent proteins connected with the target are 
often used. The resolution is sufficient to discriminate the organelle inside the living 
cells. However, it is not a suitable tool to evaluate the time dependent change of p53 
mitochondrial translocation in cell populations because of the probability of 
fluorescence bleaching by excitation light. 
Bioluminescent probes have the advantages of low background, high 
signal-to-noise ratio and wide dynamic range of signals (Ozawa et al. 2013), potentially 
applicable to high-throughput drug screening. Bioluminescent probes used in a 
protein-fragment complementation assay (PCA) may be particularly useful in the 
analysis of protein-protein interactions, protein localization, detection and the 
monitoring of the activity of steroid hormones and of second messengers (Wehr and 
Rossner 2016). To perform high-throughput drug screening using luciferase fragment 
complementation assays, a pair of luciferase fragments is required that emits a strong 
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luminescence signal upon complementation. We previously established a pair of 
luciferase fragments using the N-terminal end of a Brazilian click beetle (Emerald Luc; 
ELuc) (Nakajima et al. 2010; Viviani et al. 1999) and the C-terminal end of a Caribbean 
red click beetle luciferase (CBR) with three point mutations (multiple-complement 
luciferase fragment; McLuc1) (Hida et al. 2009). The usefulness of McLuc1 was 
demonstrated by the complementation with ELucN, CBRN or the N-terminus of firefly 
luciferase (FLucN). 
In this study, we show a new pair of luciferase fragments using the N-terminus 
of Caribbean green click beetle luciferase CBG68 (CBGN) for complementation with 
McLuc1 to achieve enhanced luminescence for a highly sensitive PCA in single living 
cells. The CBGN-McLuc1 pair was used for monitoring p53 translocation from the 
cytosol to mitochondria in live cells. Oxidative stress induced mitochondrial 
translocation of p53, which was detected by restoration of the luminescence signal 
through the combination of mitochondrially located CBGN with McLuc1 connected to 
p53. We investigated effects of two distinct inhibitors of p53, pifithrin-μ (PFT-μ) (Strom 
et al. 2006) and pifithrin-α (PFT-α) (Komarov et al. 1999), on the p53 translocation into 
mitochondria. The PFT-μ is believed to affect the p53 translocation to mitochondria 
under oxidative stress. We show direct evidence that mitochondrial translocation of p53 
is inhibited by PFT-µ in a concentration-dependent manner. The potential applicability 
to screening different chemicals using the probe is discussed. 
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RESULTS  
    A New Pair of Luciferase Fragments for Highly Sensitive Complementation 
Assays. We previously developed a pair of bioluminescent probes to assess 
protein-protein interactions using luciferase fragment of ELucN (1-412 amino acids; aa) 
together with McLuc1 (395-542 aa). The bioluminescent probes showed a high 
signal-to-background (S/B) ratio upon protein-protein interactions (Hida et al. 2009). 
Nevertheless the luminescence intensity of the ELucN-McLuc1 combination was not 
sufficient for visualizing protein-protein interactions at a single cell level with 
bioluminescence microscopy. The McLuc1 is originated from CBR with three point 
mutations, and CBG and CBR are based on a luciferase gene originally cloned from a 
Caribbean click beetle Pyrophorus plagiophthalamus. Therefore, we predicted that the 
CBGN fragment has a potential to complement to McLuc1 with higher efficiency. To 
improve the signal sensitivity, we used CBGN (1-413 aa) instead of ELucN to 
complement with McLuc1 and generated a CBGN_FKBP vector (Figure 1). To compare 
the luminescence intensities upon complementation, we used rapamycin-induced 
interaction between FK506-binding protein (FKBP) and FKBP-binding domain (FRB) 
(Banaszynski et al. 2005; Hida et al. 2009). Human embryonic kidney (HEK) 293T cells 
were co-transfected with ELucN_FKBP and FRB_McLuc1 or CBGN_FKBP and 
FRB_McLuc1 vectors. After 2 days incubation, the cells were treated with 1 μM 
rapamycin or dimethyl sulfoxide (DMSO, control), and the luminescence intensities 
were measured using a microplate reader (Figure 2). The S/B ratio of the 
ELucN-McLuc1 compared to CBGN-McLuc1 complementation was similar; however, 
with CBGN-McLuc1 complementation, rapamycin-treated cells showed an 11-fold 
increase in luminescence over vehicle control. In addition, the luminescence intensity 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 
This article is protected by copyright. All rights reserved 
from the CBGN-McLuc1 complementation was ~8-fold higher than the 
ELucN-McLuc1 complementation in rapamycin-treated cells. These results indicate that 
CBGN-McLuc1 complementation is more efficient and likely to be more useful in 
bioluminescence PCAs notably for imaging protein-protein interactions in living cells.  
 
    Basic Scheme for Monitoring p53 Translocation into Mitochondria with Novel 
Luciferase-fragment Complementation. We constructed a set of novel probes for 
monitoring p53 translocation from the cytosol into mitochondria using the new 
CBGN-McLuc1 complementation pair (Figure 3a). HEK293T cells were co-transfected 
with MITO_CBGN and p53_McLuc1. The luciferase fragment of CBGN is localized in 
the mitochondria as a result of MITO (a mitochondrial matrix targeting signal) (Ozawa 
et al. 2003). Upon H2O2 treatment of transfected cells, p53_McLuc1 moves into 
mitochondria, where McLuc1 complements with CBGN resulting in emission of 
bioluminescence (Figure 3b). 
 
    Luminescence Intensity of CBGN-McLuc1 Complementation Depends on p53 
Translocation from the Cytosol into Mitochondria under H2O2 Treatment. To 
confirm whether the p53_McLuc1 probe translocates into mitochondria and emits 
luminescence in living cells, HEK293T cells were transiently co-transfected with 
p53_McLuc1 and MITO_CBGN. The transfected cells were treated with different 
concentrations of H2O2 (0.05, 0.1, 0.2 or 0.4 mM) or deionized water (dw, control), and 
their luminescence intensities measured with a microplate reader (Figure 4a). The 
intensity of the cells transfected with the MITO_CBGN and p53_McLuc1 started to 
increase immediately following 0.2 or 0.4 mM H2O2 treatment (p < 0.01 vs. respective 
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vehicle control). On the other hand, the intensity of the cells treated with 0.05 and 0.1 
mM H2O2 started to increase at 15 min and 10 min, respectively (p < 0.01 vs. respective 
vehicle control). This demonstrates an efficient complementation of CBGN-McLuc1 
fragments upon p53 translocation into mitochondria. The luminescence intensities were 
statistically analyzed at every time point and quantified (Figure 4a, right) at 120 min 
when signal reached a plateau (Figure 4a, left). The luminescence of the cells treated 
with 0.1-0.4 mM H2O2 showed significant increases compared to that of 0.05 mM H2O2 
(Figure 4a, right). Consequently, dose of 0.1 mM H2O2 was used for oxidative stress in 
the subsequent experiments. 
To evaluate the direct effects of H2O2 on luciferase activity, full-length CBG 
luciferase was expressed in mitochondria by transfecting cells with MITO_CBG and 
stimulated with H2O2 under the same experimental conditions. Although no change in 
luminescence signal was observed in the vehicle control, the luminescence intensity of 
the cells significantly decreased 129 min after treatment of the cells with 0.1 mM H2O2 
(p < 0.05 vs. vehicle control) (Figure 4b). These results indicate that H2O2 in the 
0.05-0.4 mM concentration range partly inhibited luciferin-luciferase reaction in 
HEK293T cells. As the bioluminescence is an ATP-dependent process and ATP is 
produced by mitochondria, the observed small decrease in luminescence could result 
from oxidative mitochondrial damage. Therefore, the luminescence intensities can be 
measured over 120 min after H2O2 treatment. 
To exclude a possibility that the elevation of the luminescence intensity 
originated from an increase in the amount of the luciferase probes, we analyzed the 
protein levels of the cells expressed p53_McLuc1 and MITO_CBGN under the same 
conditions at 120 min (Figure 4c). No significant change in the protein level was 
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observed in the presence or absence of H2O2. Taken these results together, we conclude 
that the luminescence signal from the CBGN-McLuc1 complementation originates from 
p53 translocation from the cytosol into the mitochondrial matrix induced by oxidative 
stress.  
     
     Effect of PFT-μ and PFT-α on the p53 Translocation into Mitochondria. 
Next, to demonstrate the applicability of the p53 translocation probes for chemical 
library screening, we investigated the inhibitory effects of known p53 inhibitors on p53 
translocation into mitochondria. The cells transfected with p53_McLuc1 and 
MITO_CBGN were treated with different concentrations of PFT-μ or DMSO for 1 h 
and then stimulated with H2O2. PFT-μ caused a reduction in luminescence intensity in a 
concentration-dependent manner, with luminescence completely abolished at 40 μM 
PFT-μ (Figure 5a). When cells expressing full-length CBG68 were exposed to H2O2 in 
the presence of PFT-μ, no significant difference in luminescence was observed 
regardless of the concentration of PFT-μ (Figure 5b), indicating that PFT-μ did not 
interfere with the luciferase activity in mitochondria. We also analyzed protein levels of 
p53_McLuc1 and MITO_CBGN in cells treated with PFT-μ before H2O2 exposure and 
found no difference in protein levels in the presence or absence of PFT-μ (Figure 5c). 
These results indicate that PFT-μ did not interfere with the reporter functions of 
luciferase in these cells but rather that PFT-µ inhibits p53 translocation into the 
mitochondrial matrix, rendering McLuc1 unable to complement with the mitochondrial 
localized CBGN in HEK293T cells to generate luminescence.  
PFT-α inhibits p53 mediated transcriptional activation and apoptosis (Komarov 
et al. 1999). It is not clear, however, whether PFT-α also inhibits p53 translocation to 
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mitochondria. Using our probes, we evaluated the effect of PFT-α on p53 translocation 
into mitochondria in HEK293T cells. Cells transfected with p53_McLuc1 and 
MITO_CBGN were treated with different concentrations of PFT-α or DMSO for 1 h 
and exposed to H2O2 thereafter. PFT-α, even at 20 µM, was unable to reduce 
luminescence induced by H2O2 (Figure 6a). This indicates that PFT-α does not inhibit 
p53 translocation from the cytosol into mitochondria. We also examined the effect of 
PFT-α on the luciferin-luciferase reaction using the full-length CBG luciferase. No 
significant increase in luminescence intensities was observed regardless of the 
concentration of PFT-α (Figure 6b). All these results indicate that PFT-α neither 
interferes with luciferase activity nor inhibits p53 translocation into mitochondria. 
 
    Time-lapse Bioluminescence Imaging of p53 Translocation into Mitochondria. 
For measurement of bioluminescence using a pair of luciferases emitting different 
wavelengths, filters are set to select a particular wavelength in the microscopic system, 
based on the bioluminescence spectrum of each luciferase. To enable future use of the 
CBGN-McLuc1 complemented luciferase with other luciferases, we analyzed the 
bioluminescence spectrum of the CBGN-McLuc1 complemented luciferase. HEK293T 
cells were transiently co-transfected with p53_McLuc1 and MITO_CBGN, then the 
emission spectrum of the cell lysates was determined, exhibiting green light with an 
emission maximum at 556 nm (Figure 7), unlike CBG68 luciferase that has an emission 
maximum of 537 nm. The spectral shift at 19 nm may originate from the use of McLuc1, 
generated from the C-terminus of the CBR with three point mutations. 
  To temporally monitor p53 translocation into mitochondria using the 
bioluminescent probe, time-lapse images of cells expressing p53_McLuc1 and 
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MITO_CBGN were obtained sequentially in the presence or absence of 0.1 mM H2O2 at 
single cell level (Figure 8 and Supporting Video 1, 2). As observed with the microplate 
reader, the luminescence intensity of the cells significantly increased upon addition of 
H2O2 from 20 min onward under the microscope (Figure 8a, b). On the other hand, the 
cells treated with vehicle showed no significant difference in luminescence. Although 
the subcellular localization of the probes was limited by optical resolution and long 
exposure times, bioluminescence imaging of HEK293T cells transfected with 
p53_McLuc1 and MITO_CBGN captured translocation of p53 at the single cell level.  
 
DISCUSSION 
     Protein translocation from one subcellular compartment to another in 
response to a physiological signal or under stress is a fundamental cellular process 
required in the regulation of complex biological systems within living organisms. New 
technologies and functional assays have always been needed to monitor dynamic cellular 
processes, such as protein translocation and protein-protein interactions, in real-time in 
the physiological environment of live cells. P53 transcriptional activities affected via the 
nucleus, such as cell cycle arrest and apoptotic cell death regulation, have been well 
characterized for many years. Transcriptional independent matrix-based p53 activity for 
promoting necrotic cell death in response to oxidative stress, however, is relatively a new 
addition in functional activities of p53 (Marchenko and Moll 2014). The new, improved, 
bioluminescent protein-fragment complementation pair that we report here allowed 
real-time assays and imaging of transcriptionally independent activity of p53 in live cells. 
Unlike techniques used to evaluate p53 translocation phenomena using fixed cells or cell 
lysates where H2O2 treatment is required for 4-6 hours (Guo et al. 2014; Vaseva et al. 
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2012), p53 translocation can be monitored in our technique as soon as 15 minutes with 
very low concentration of H2O2, because of efficient complementation of the new 
luciferase fragments. It has been reported that p53 translocation to mitochondria occurs 
within 10 min after 12-O-tetradecanoylphorbol-13-acetate treatment for oxidative stress 
(Zhao et al. 2005). Although the stimulus is different from oxidative stress in our system, 
the result in terms of the time scale was consistent with the previous ones. In 
radiosensitive organs, thymus and spleen, p53 translocation to mitochondria is detectable 
at 30 min after γ-irradiation (Erster et al. 2004). Our p53 probe will be applicable to 
detection of the p53 with more rapid dynamic motion in the organs.  
Upon oxidative stress, p53 monoubiquitylated by MDM2 (a p53 ubiquitin E3 
ligase) is promoted the translocation to mitochondria (Marchenko et al. 2007). 
MDM2-mediated p53 monoubiquitylation is mediated by Drp1 (dynamin-related protein 
1) (Dashzeveg and Yoshida 2015; Guo et al. 2014). Our p53 probe may contribute to 
further elucidation of p53 mitochondrial translocation mechanism. 
Functional p53 is highly desirable for effective anticancer treatment targeted at 
the induction of death in tumor cells (Bieging et al. 2014). However, p53 expression in 
normal tissues and organs makes these vulnerable to damage from anticancer therapy 
(Chow et al. 2000; Komarova et al. 1997; Song and Lambert 1999). To minimize the 
side effects of chemo- and radiotherapy on normal tissue, inhibition of p53 
mitochondrial translocation or temporary suppression of its transcriptional activity 
could be useful. The p53 inhibitor PFT-µ is capable of maintaining the mitochondrial 
integrity and prevents both paclitaxel and cisplatin-induced mechanical allodynia 
(Krukowski et al. 2015). A single dose of PFT-µ is able to significantly reduce in vitro 
thymocyte death and in vivo lethality in mice induced by gamma irradiation (Strom et al. 
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2006). Inhibition of p53 with PFT-µ has also shown promising results using rat neonatal 
brain ischemia to model perinatal hypoxia/asphyxia-induced brain damage (Nijboer et al. 
2011). Here, we have succeeded in showing direct evidence in live cells that PFT-μ 
inhibits the translocation of p53 from cytosol into mitochondria under H2O2 exposure. 
Hence, the developed p53 probe allows for exploration of novel inhibitors for 
mitochondrial translocation of p53. In contrast, p53 transcriptional inhibitor, PFT-α, did 
not prevent the mitochondrial translocation of the p53 probe under oxidative stress in 
HEK293T cells. This result is in reasonable agreement with the effects of PFT-α, which 
blocks p53-dependent transcriptional activation and apoptosis (Komarov et al. 1999). 
Taken together, the present PCA for monitoring p53 mitochondrial translocation is a 
novel tool that may be used effectively in live cells for high-throughput screening on the 
identification of mitochondrial p53 inhibitors, in the search for drugs to prevent or 
reduce necrotic cell death in a range of acute and chronic diseases as in reducing side 
effects of anticancer therapies. 
There are some available PCA-based tools such as β-lactamase (Remy et al. 
2007) and β-galactosidase (Rossi et al. 1997). Since PCAs using β-lactamase and 
β-galactosidase are performed by use of the fluorescent substrates in living cells, 
long-term measurement for high-throughput screening is not suited. Moreover, 
β-galactosidase is high molecular weight (116 kDa) compared to FLuc (61 kDa) and 
CBG68 (60 kDa). In contrast, NanoLuc (Nluc) was engineered from the deep sea 
shrimp Oplophorus gracilirostris as a small luciferase subunit (19 kDa), which showed 
an activity greater than that of either firefly or Renilla luciferases (Hall et al. 2012). 
However, a short half-life, within 4 h at 37C, of Nluc substrate (furimazine, a 
coelenterazine analog) could limit its applications for long-term monitoring. By contrast, 
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D-luciferin is a quite stable substrate compared to Cypridina luciferin and the luciferins 
of krill and dinoflagellates (Shimomura 2012). Thus, the luciferases with D-luciferin as 
a substrate are suitable for high-throughput drug screening. 
Finally, we optimized the luciferase fragments to boost overall photon 
productions. It has been reported that CBG99N (2-413 aa) complemented with 
CBG99C (395-542 aa), and the CBG99C was used for dual-color luciferase PCAs 
(Villalobos et al. 2010). CBG99 includes one amino acid difference compared to the 
amino acids of CBG68. Also, CBG99C does not complement with the FLucN 
(Villalobos et al. 2010). In contrast, McLuc1 can complement with ELucN, CBRN, 
FLucN (Hida et al. 2009), or CBGN. Thus, the new pair of CBGN and McLuc1 will be 
applicable for dual-color luciferase fragment complementation assays for simultaneous 
detection of proteins in two different compartments of a cell. 
 
CONCLUSION 
    The new pair of luciferase fragments, CBGN and McLuc1, showed efficient 
complementation with significant bioluminescence intensity and high S/B ratio, which 
allowed direct monitoring and visualization of p53 translocation from the cytosol into 
mitochondrial matrix in living cells subjected to oxidative stress. The assay specificity 
has been demonstrated by using two distinct p53 inhibitors. The present PCA can serve 
as a new tool for high-throughput screening on the identification of specific p53 
inhibitors for the development of drugs to protect mitochondrial function during the 
pathogenesis of different diseases. 
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METHODS 
    Vector Construction. FKBP binds with FRB in the presence of rapamycin. 
Previously, we constructed CBRN_FKBP and FRB_McLuc1 vectors to evaluate the 
complementation of the CBRN-McLuc1 fragments. McLuc1 was developed from the 
C-terminus of the CBR by introducing three point mutations, F420I, G421A and E453S 
(Hida et al. 2009). To generate CBGN, the DNA fragment encoding the N-terminus 
(1-413 aa) of the CBG68 was amplified by PCR using the pCBG68-Basic vector 
(Promega) as a template. The CBRN in the CBRN_FKBP was replaced with the 
amplified CBGN to construct the CBGN_FKBP. The CBGN_FKBP and FRB_McLuc1 
were used to evaluate the complementation efficiency of the CBGN and McLuc1 
fragments. 
    A hygromycin B resistance gene was amplified by PCR using pQCXIH vector 
(Takara-Clontech) as a template, and a fragment of FLAG epitope tag was generated by 
oligonucleotide annealing. Myc epitope and a six-histidine (myc-His), and a neomycin 
resistance gene in pcDNA3.1/myc-His (B) vector (Thermo Fisher Scientific-Invitrogen) 
were replaced with the FLAG epitope tag and the hygromycin B resistance gene, 
respectively (pcDNA3.1_FLAG_Hygror vector). The fragment of CBGN and full-length 
CBG were amplified by PCR, and fragments of a MITO were generated by 
oligonucleotide annealing. The MITO translocates into the mitochondrial matrix 
(Ozawa et al. 2003). The MITO and CBGN or full-length CBG were inserted into 
pcDNA3.1_FLAG_Hygror vector. A puromycin resistance gene was amplified by PCR 
using pLVSIN-CMV pur vector (Takara) as a template, which was replaced with a 
Zeocin resistance gene in pcDNA4/V5-His (B) vector (Thermo Fisher 
Scientific-Invitrogen). Human p53 (NCBI reference sequence: NP_000537.3) and 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
16 
This article is protected by copyright. All rights reserved 
McLuc1 were amplified by PCR using Human Brain, whole QUICK-Clone cDNA 
(Clontech) and FRB_McLuc1 as templates, respectively. These fragments were inserted 
into the modified pcDNA4/V5-His (B) vector.  
 
    Cell Cultures and Transfection. HEK293T cells were obtained from Abcam and 
maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% 
fetal bovine serum (FBS) and penicillin–streptomycin (100 units/ml and 100 g/ml, 
respectively) under 5% CO2 at 37C. The constructed vectors were transfected into 
HEK293T cells using TransIT-LT1 reagent (Takara-Mirus) according to the 
manufacturer’s instructions.  
 
    Rapamycin, PFT-μ, or PFT-α Treatment and Luciferase Assay. The 
luminescence intensities by complementation of CBGN and McLuc1 fragments or 
ELucN and McLuc1 fragments were evaluated based on FKBP-FRB interactions. ELuc 
(Toyobo) is a green-emitting luciferase (λmax=538 nm) (Nakajima et al. 2010; Viviani et 
al. 1999). 
HEK293T cells were spread on a 96-well microtiter plate and cultured in 
DMEM supplemented with 10% FBS and penicillin–streptomycin for 1 day. The cells 
were transiently co-transfected with CBGN_FKBP and FRB_McLuc1 or ELucN_FKBP 
and FRB_McLuc1, respectively, for 2 days, and the medium of the cells was replaced 
with phenol red-free DMEM containing 25 mM HEPES (Thermo Fisher 
Scientific-Gibco), 1 μM rapamycin (Santa Cruz Biotechnology) or DMSO (vehicle 
control), and 0.2 mM D-luciferin. Luminescence intensity was measured with a 
microplate reader, Mithras LB 940 (Berthold technologies), at room temperature at 30 
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min after the treatment.  
The cells were transiently co-transfected with MITO_CBGN and p53_McLuc1 
vectors for 24 h, which was treated with phenol red-free DMEM containing 25 mM 
HEPES, 0.2 mM D-luciferin, and 0.05, 0.1, 0.2 or 0.4 mM H2O2 (for oxidative stress) or 
dw (vehicle control). The luminescence intensity was measured with a microplate reader 
at room temperature for 4 h. As exposure to drugs, the transfected cells were treated 
with various concentrations of p53 inhibitors, PFT-µ (Sigma-Aldrich) or PFT-α 
(Millipore.Com/Calbiochem), for 1 h, and then the luminescence intensity of the cells 
was measured at room temperature for 2 h with or without 0.1 mM H2O2. 
 
    Western Blotting. HEK293T cells were lysed with RIPA buffer containing protease 
inhibitor cocktail, Complete EDTA-free (Roche), and centrifuged at 15,000 rpm at 4C 
for 10 min. The supernatants of the cells were boiled for 5 min, which was separated by 
sodium dodecyl sulfate–polyacrylamide gel electrophoresis and transferred to a 
nitrocellulose membrane. The membrane was blocked with 5% skim milk for 1 h. 
Western blot analysis was performed using anti-V5 antibody (Themo Fisher 
Scientific-Novex), anti-DDDDK-tag pAb antibody (MEDICAL & BIOLOGICAL 
LABORATORIES CO., LTD.), and anti-beta-actin antibody (Sigma-Aldrich). The 
protein levels were measured by LAS 4000 mini (GE Healthcare). 
 
Spectral Measurements. HEK293T cells were spread on 35-mm culture dishes 
and cultured in DMEM supplemented with 10% FBS and penicillin-streptomycin for 1 
day under 5% CO2 at 37C. The cells were transiently co-transfected with the 
MITO_CBGN and p53_McLuc1. After 24 h of the transfection, the cells were treated 
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with phenol red-free DMEM containing 25 mM HEPES and 0.1 mM H2O2 for 1 h under 
5% CO2 at 37C. The cells were lysed by Bright-Glo Luciferase Assay System 
(Promega) and transferred to 0.2 ml tubes. The tubes were placed on the sample stage of 
a spectrophotometer (AB-1850; ATTO), and the spectra were acquired for 10 min with 
a slit width of 1 mm. To measure background of the luminescence, untransfected cells 
of HEK293T were used. The spectral smoothing was performed by the Savitzky-Golay 
filtering algorithm with a window length of 41 data points.  
 
    Single Cell Imaging. HEK293T cells were plated on a poly-L-lysine-coated 
glass-base dish (IWAKI) and then cultured for 1 day. The cells were transiently 
co-transfected with MITO_CBGN and p53_McLuc1 for 1 day, and the medium was 
replaced with phenol red-free DMEM containing 0.2 mM D-luciferin and 1% FBS. The 
luminescence of the complemented luciferase was directly imaged with an inverted 
fluorescence and luminescence microscope (IX81; Olympus Corp.) using a 20× 
oil-immersion objective (0.85 NA) at room temperature (23C). Digital images were 
acquired with electron multiplying charge-coupled device (EM-CCD) camera 
(ImagEM; Hamamatsu Photonics K.K.). Luminescence images were acquired every 10 
min using 9-min exposure time; bright field (differential interference contrast) images 
were taken for 150 ms. After the images were acquired for 1 h, the cells were treated 
with 0.1 mM H2O2 or dw by the instillation and acquired the images for 2 h. All 
luminescence images were analyzed the bioluminescence intensity of single cells using 
the imaging software (Meta Morph; Molecular Devices Corp.) and merged with bright 
field images.  
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    Statistical analysis. Paired group data were analyzed using Welch’s t-tests after 
F-tests were used to evaluate whether the variances were equivalent. Data of multiple 
groups were analyzed one-way ANOVA. Two-series of data were analyzed by repeated 
measure two-way ANOVA with a multiple comparison test, Scheffe or 
Bonferroni/Dunn procedure.  
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FIGURE LEGENDS 
Figure 1.  Schematic of luciferase fragment complementation assays based on the 
FKBP-FRB interactions. Rapamycin induces binding of FKBP to FRB, which causes 
the complementation of CBGN and McLuc1, resulting in the restoration of the 
luminescence. V5/His indicates an epitope tag (V5) and a tag composed of six histidine 
residues (His), respectively. 
Figure 2. Comparison of luminescence intensity of rapamycin-induced luciferase 
complementation. HEK293T cells were spread on a 96-well microtiter plate and 
transiently co-transfected with ELucN_FKBP and FRB_McLuc1, or CBGN_FKBP and 
FRB_McLuc1, respectively, for 2 days under 5% CO2 at 37C. The medium was 
replaced with phenol red-free DMEM containing 25 mM HEPES, 1 μM rapamycin or 
DMSO, as a vehicle control, and 0.2 mM D-luciferin. The luminescence was measured 
with a microplate reader at 30 min after the treatment. Data were expressed as mean ± 
SD (n=5). **: p < 0.01.  
Figure 3. Schematic of luciferase fragment complementation assays via p53 
translocation into mitochondrial matrix. (a) Schematic diagrams of the constructs, 
MITO_CBGN, p53_McLuc1, and MITO_CBG, to evaluate p53 translocation into 
mitochondria. MITO_CBG vector was constructed to confirm whether H2O2 interfered 
with the luciferin-luciferase reaction. These vectors are driven by cytomegalovirus 
promoter. MITO indicates a mitochondrial matrix targeting signal. (b) When the cells 
transfected with p53_McLuc1 and MITO_CBGN are stimulated with H2O2, 
p53_McLuc1 translocates into mitochondrial matrix, where McLuc1 complements with 
mitochondrial localized CBGN and results in bioluminescence. FLAG and V5/His 
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indicate epitope tags (FLAG and V5) and a tag composed of six histidine residues (His), 
respectively.  
 
Figure 4. Luminescence intensity of CBGN-McLuc1 complementation depending 
on p53 translocation into mitochondrial matrix by H2O2. (a-c) HEK293T cells were 
transiently transfected with p53_McLuc1 and MITO_CBGN (a, c) or MITO_CBG (b), 
respectively, for 24 h under 5% CO2 at 37C, the medium of which was replaced with 
phenol red-free DMEM containing 25 mM HEPES, 0.05, 0.1, 0.2, or 0.4 mM H2O2 or 
dw, as a vehicle control, and 0.2 mM D-luciferin. (a, b) The luminescence intensity of 
the cells was measured with a microplate reader for 4 h. Data were expressed as mean ± 
SD (n=5). (a, right) Bar graph indicates the light intensity of H2O2-treated cells 
expressing p53_McLuc1 and MITO_CBGN at 120 min in the left graph. **: p < 0.01 
vs. respective vehicle. ++: p < 0.01. (c) The amount of protein was analyzed by Western 
blotting at 120 min after H2O2 treatment. ‘-’ and ‘veh’ indicate untransfected cells and 
vehicle control, respectively (a-c).  
Figure 5. Decrease in luminescence intensity based on inhibition of p53 
translocation from cytosol into mitochondrial matrix by PFT-μ. (a-c) HEK293T 
cells were transiently transfected with p53_McLuc1 and MITO_CBGN (a, c) or 
MITO_CBG (b), respectively, for 24 h under 5% CO2 at 37C, the medium of which 
was replaced with phenol red-free DMEM containing 25 mM HEPES and 10, 20, or 40 
μM PFT-μ or DMSO (vehicle control) for 1 h. The medium of the cells was exchanged 
with phenol red-free DMEM containing 0.1 mM H2O2 or dw (vehicle control) and 0.2 
mM D-luciferin. (a, b) The luminescence intensity of the cells was measured with a 
microplate reader for 2 h. Data were expressed as mean ± SD (n = 6; untransfected cells, 
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n = 4). (a, right) Bar graph indicates the light intensity of H2O2-treated cells with or 
without PFT-μ expressing p53_McLuc1 and MITO_CBGN at 120 min in the left graph. 
**: p < 0.01 vs. respective vehicle under 0.1 mM H2O2 treatment. ++: p < 0.01. (c) The 
amount of protein was analyzed by Western blotting at 90 min after H2O2 treatment. ‘-’ 
and ‘veh’ indicate untransfected cells and vehicle control, respectively (a, c).  
Figure 6. Luminescence intensity based on p53 translocation into mitochondrial 
matrix using PFT-α-treated cells. (a, b) HEK293T cells were transiently transfected 
with p53_McLuc1 and MITO_CBGN (a) or MITO_CBG (b), respectively, for 24 h 
under 5% CO2 at 37C, the medium of which was replaced with phenol red-free DMEM 
containing 25 mM HEPES and 5, 10, or 20 μM PFT-α or DMSO (vehicle control) for 1 
h. The medium of the cells was exchanged with phenol red-free DMEM containing 0.1 
mM H2O2 or dw, as a vehicle control, and 0.2 mM D-luciferin, and the luminescence 
intensity of the cells was measured with a microplate reader for 2 h. Data were 
expressed as mean ± SD (n=5). (a, right) Bar graph indicates the light intensity of 
H2O2-treated cells with or without PFT-α expressing p53_McLuc1 and MITO_CBGN at 
120 min in the left graph. ‘-’ indicates untransfected cells. 
Figure 7. Emission spectrum of the luciferase based on CBGN-McLuc1 
complementation. HEK293T cells were transiently co-transfected with p53_McLuc1 
and MITO_CBGN for 24 h. The medium of the cells was replaced with phenol red-free 
DMEM containing 25 mM HEPES and 0.1 mM H2O2 and then incubated for 1 h under 
5% CO2 at 37C. The cells were lysed with a reagent containing luciferin, and the 
luminescence spectrum was measured using a spectrophotometer. The data smoothing 
was performed by the Savitzky-Golay (S-G) filtering algorithm (green line). The 
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magenta line indicates the raw data of the luminescence spectrum based on 
CBGN-McLuc1 complementation.  
Figure 8. Time-lapse bioluminescence imaging of CBGN-McLuc1 
complementation depending on p53 translocation into the mitochondrial matrix by 
H2O2 treatment at a single cell level. (a, b) HEK293T cells were plated on a glass-base 
dish and then cultured for 1 day. The cells were transiently co-transfected with 
p53_McLuc1 and MITO_CBGN for 24 h, and the medium was replaced with phenol 
red-free DMEM containing 0.2 mM D-luciferin and 1% FBS. After the bioluminescence 
imaging was acquired at a single cell level for 1 h, the cells were treated with 0.1 mM 
H2O2 or dw and then acquired the images for 2 h. The imaging data was obtained every 
10 min using 9-min exposure time. Time 0 indicates the initiation of the time-lapse 
bioluminescence imaging. Arrow represents the initiation of H2O2 treatment. (a) The 
light intensity of individual cells was shown as the relative value. (b) The light intensity 
of three individual cells was shown as mean ± SD. **: p < 0.01 vs. respective vehicle 
control. 
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